Though not reaching the overall surival endpoint in Phase III, the European Commission has granted label extension for Roche’s checkpoint blocker Tecentriq in two types of metastatic bladder cancer.
French microbiota specialist Da Volterra has received an EIB loan to speed up development of treatments that prevent antibiotic resistance and hospital acquired infections.
A team of US and German researchers has found that neutrophils secrete a regulatory RNA into lung tissue that protects against harmful inflammations.
Healthcare investor Vesalius Biocapital has created a new investment vehicle in collaboration with the Portuguese National Promotional bank (IFD) aimed at investing in Portuguese life science companies.
British T cell receptor specialist Immunocore Ltd will receive a US$40m investment from the the Bill & Melinda Gates Foundation to develop immunotherapies that fight tuberculosis and HIV.
.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) published the results of its September meeting.
The European Medicine Agency’s CHMP has rejected a type II extension application to Santhera Pharmaceutical’s coenzyme Q10 analogon idebenone (Raxone) as treatment for patients with Duchenne muscular dystrophy (DMD). Raxone was approved under exceptional circucumstances in September 2015 to treat visual impairment in patients with the rare eye disease LHON.
Artificial intelligence (AI) specialist Sophia Genetics SA (St. Sulpice, Switzerland) raised US$30m in a series D round to foster global expansion of its cancer diagnostics annotation platform SOPHiA AI.
Two research team independently report they have identified specific microbes in the gut of mice and of treatment-naive patients with multiple sclerosis (MS) regulating immune responses. Phase I trails with fecal microbial transplants (FMT) are scheduled to begin early next year.
Thermo Fisher Scientific has extended its Next Generation Sequencing Companion Dx Center of Excellence Programme (COEP) in Europe. The next-generation sequencing (NGS) provider added a second agreement with the Institute of Pathology Heidelberg (IPH) to its growing COEP portfolio. On the same day, Merck KGaA announced it will partner with Project Data Sphere LLC to jointly lead the Global Oncology Big Data Alliance (GOBDA).